Healthcare Industry News: coronary sidebranch
News Release - February 11, 2011
Cappella Medical Announces New Sideguard(R) Clinical Data on Bifurcation Plaque RedistributionGALWAY, Ireland--(Healthcare Sales & Marketing Network)-- Cappella Medical Devices presented new clinical data on its unique Sideguard® coronary sidebranch system today at the International JIM 2011 (Joint Interventional Meeting) in Rome, Italy. The new study titled Bifurcation Plaque Redistribution: An Intravascular Ultrasound Comparison of the Self-expanding Sideguard® Stent in the Sidebranch Versus a Balloon-Expandable Stent in the Main Vessel was presented by a group of investigators led by Gary Mintz, MD (Colombia University Medical Center/Cardiology Research Foundation, New York, NY).
The study measured the effects of balloon expandable and self-expanding Sideguard nitinol stents on the vessel wall. The IVUS data showed that the trumpet-shaped self-expanding Sideguard stent contributed to vessel remodeling and also reduced plaque redistribution and carina shift when the Sideguard was placed in the coronary sidebranch vessel as a first line treatment. Dr. Gary Mintz stated that the, “Expansion of a balloon expandable stent in the main vessel of a bifurcation lesion was associated with axial plaque distribution that was not seen with the corresponding sidebranch treated with the Sideguard stent. Long term follow up will determine the impact of this phenomenon on ostial sidebranch stenosis.” The full study results will be presented in May 2011 at the EuroPCR meeting in Paris.
Michael Gilmore, Vice President of R&D, Clinical, and Regulatory at Cappella Medical, said, “The Cappella Sideguard coronary sidebranch technology was developed to protect the ostium of the sidebranch which, in turn, will preserve the sidebranch coronary artery. The clinical data that was presented today validates our belief that the Sideguard addresses an unmet need for the protection, and preservation, of the coronary sidebranch artery. We look forward to additional clinical data in the coming months.”
About Cappella Medical Devices
Cappella, Inc. is a medical device company that develops novel solutions for the treatment of complex coronary artery disease (CAD) focused on protecting the coronary sidebranch arteries. Cappella’s Sideguard® coronary sidebranch technology offers interventional cardiologists a straightforward, effective, and easy to use solution that preserves the sidebranch of diseased coronary arteries by protecting the ostium while minimizing plaque shift. The Sideguard delivery system features a proprietary split-sheath, balloon released, technology that ensures precise placement on the ostial borderline. The Sideguard self-expanding, nitinol, stent promotes continuous wall apposition and positive remodeling and its unique trumpet-shaped design conforms to varying characteristics of the sidebranch ostium. Cappella Medical Devices Ltd., Galway, Ireland is the R&D and manufacturing subsidiary of Cappella, Inc. For more information, please visit the Cappella Medical Systems website at www.cappella-med.com.
Source: Cappella Medical Devices
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.